Vinod Metta image

Dr Vinod Metta

Consultant Interventional Neurologist & Movement Disorders Specialist


Year qualified:


GMC No. or equivalent


Primary speciality:


Specialist interests:

Movement Disorders, Parkinson’s disease, advanced therapies (Infusional, therapies in Parkinson) Dystonia, Botulinum injections specialist.

Other Interests - General Neurology, Neuro-Opthalmology, Autonomic Disorders, Sleep Disorders




Professional memberships:

Royal College of Physicians (UK) Association of British Neurologists (ABN)

World Federation of Neurology (WFN)

Consulting address:

Guthrie Clinic
King's College Hospital
NHS Foundation Trust
Denmark Hill
London SE5 9RS

Clinic times:

Wednesday and Friday's


Dr Vinod Metta is a Consultant Interventional Neurologist and Movement Disorder Specialist. He trained at King's College Hospital and conducted his higher specialist training in neurology and movement disorders at Imperial College London, University College London and Queen Square Hospitals in London. 

He is a member of the Association of British Neurologists (ABN) and a Fellow of the Australian and New Zealand Association of Neurologists (ANZAN). He was awarded his doctorate for research on the pathophysiology of, and treatment options for, disabling non-motor symptoms of fatigue and sleep in patients with Parkinson’s disease, in collaboration with King's and Imperial College London. He was a recipient of the 2016 ABN Australasian Fellowship.

Dr Metta has authored and co-authored several papers published in high-impact factor journals such as Brain, several book chapters, including in the Oxford Textbook for Clinical Medicine 5th and 6th editions, and a book titled Parkinson’s Disease – The Hidden Face. He has been appointed to the editorial board of the Journal of Parkinson’s Disease, and he serves on several advisory board committees. 

He is a postgraduate tutor at Imperial College London, and runs several MRCP courses nationally and internationally. He has a particular interest in exploring and pioneering biomarkers to investigate pathophysiology and treatment models of neurodegenerative disorders.


2016 - 2023 © King's College Hospital NHS Foundation Trust